| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Bernd Kowall, Gregor Maier, Wolfgang Rathman. Too good to be true: Are GLP-1 receptor agonists the new metformin? Journal of diabetes and its complications. vol 38. issue 10. 2024-09-05. PMID:39236411. |
recently, a health-care database study showed that persons with type 2 diabetes taking glp-1 receptor agonists (glp-1 ra) had a significantly lower risk of 10 out of 13 obesity-related cancers than patients taking insulin (wang l, et al. |
2024-09-05 |
2024-09-08 |
Not clear |
| Bernd Kowall, Gregor Maier, Wolfgang Rathman. Too good to be true: Are GLP-1 receptor agonists the new metformin? Journal of diabetes and its complications. vol 38. issue 10. 2024-09-05. PMID:39236411. |
in the current glp-1 ra study, it was striking that the curves for the cumulative incidence of several cancers in glp-1 ra and insulin users diverged immediately after therapy onset. |
2024-09-05 |
2024-09-08 |
Not clear |
| Bernd Kowall, Gregor Maier, Wolfgang Rathman. Too good to be true: Are GLP-1 receptor agonists the new metformin? Journal of diabetes and its complications. vol 38. issue 10. 2024-09-05. PMID:39236411. |
this indicates that there is most likely a time-related bias: insulin is given at much later stages of type 2 diabetes than glp-1 ra. |
2024-09-05 |
2024-09-08 |
Not clear |
| G Krishnan, M Bagath, C Devaraj, N M Sore. The signalling association of glucagon-like peptide-1 and its receptors in the gastrointestinal tract and GPR40 and insulin receptor in the pancreas of sheep. General and comparative endocrinology. 2024-09-03. PMID:39226991. |
plasma concentrations of glp-1, insulin, glucagon, and glucose were assessed every two weeks. |
2024-09-03 |
2024-09-06 |
Not clear |
| G Krishnan, M Bagath, C Devaraj, N M Sore. The signalling association of glucagon-like peptide-1 and its receptors in the gastrointestinal tract and GPR40 and insulin receptor in the pancreas of sheep. General and comparative endocrinology. 2024-09-03. PMID:39226991. |
postprandial glp-1 and insulin were increased by 3.7-4.1 and 1.45-1.5 times, respectively, in the csfas-supplemented groups compared to csfa0. |
2024-09-03 |
2024-09-06 |
Not clear |
| G Krishnan, M Bagath, C Devaraj, N M Sore. The signalling association of glucagon-like peptide-1 and its receptors in the gastrointestinal tract and GPR40 and insulin receptor in the pancreas of sheep. General and comparative endocrinology. 2024-09-03. PMID:39226991. |
chemosensing of lcfas by gpr40 in the pancreas triggers signalling transduction, and enhanced glp-1 and glp-1r resulted in moderately increased insulin secretion and reduced glucagon levels. |
2024-09-03 |
2024-09-06 |
Not clear |
| Ying Yun, Shimeng Guo, Xin Xi. V1bR enhances glucose-stimulated insulin secretion by paracrine production of glucagon which activates GLP-1 receptor. Cell & bioscience. vol 14. issue 1. 2024-08-31. PMID:39217353. |
v1br enhances glucose-stimulated insulin secretion by paracrine production of glucagon which activates glp-1 receptor. |
2024-08-31 |
2024-09-04 |
Not clear |
| Sanghoon Park, Raksha Jain, Sasan Mirfakhrae. Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 2024-08-30. PMID:39214747. |
with the addition of glp-1 agonists, all individuals experienced weight loss and a reduction in daily insulin dose, and most had improvement in pulmonary function. |
2024-08-30 |
2024-09-04 |
Not clear |
| Amr Ahmed, Maher Monir Ak. Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression. Advanced pharmaceutical bulletin. vol 14. issue 2. 2024-08-29. PMID:39206389. |
exploring a synergistic approach: dual glp-1 agonist combined with degludec basal insulin for early type 1 diabetes treatment and its impact on albumin-insulin producing cells expression. |
2024-08-29 |
2024-09-04 |
Not clear |
| Amr Ahmed, Maher Monir Ak. Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression. Advanced pharmaceutical bulletin. vol 14. issue 2. 2024-08-29. PMID:39206389. |
this manuscript explores the potential of dual glucagon-like peptide 1 (glp-1) agonists combined with degludec basal insulin as a treatment approach for early type 1 diabetes. |
2024-08-29 |
2024-09-04 |
Not clear |
| Ahmed I Gad, Nevin F Ibrahim, Noura Almadani, Rasha Mahfouz, Hanaa A Nofal, Dina S El-Rafey, Hossam Tharwat Ali, Amr T El-Hawary, Ayman M E M Sade. Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial. Diseases (Basel, Switzerland). vol 12. issue 8. 2024-08-28. PMID:39195185. |
glp-1 receptor agonists (glp-1 ras) have been shown to improve glycemic control and insulin sensitivity and reduce body weight in obese patients with type 2 diabetes mellitus (t2d). |
2024-08-28 |
2024-08-30 |
Not clear |
| Takuya Haraguchi, Yuji Yamazaki, Hitoshi Kuwata, Ryota Usui, Yoshiyuki Hamamoto, Yutaka Seino, Daisuke Yabe, Yuichiro Yamad. Glucagon Stimulation Test and Insulin Secretory Capacity in Clinical Assessment of Incretin-Based Therapy for Diabetes. Diabetes. 2024-08-28. PMID:39196369. |
however, recent reports indicate that pharmacological concentrations of glucagon stimulate insulin secretion through glp-1 receptors, confounding the issue. |
2024-08-28 |
2024-08-30 |
Not clear |
| Aanchal Verma, Ahsas Goya. Beyond Insulin: The Intriguing Role of GLP-1 in Parkinson's Disease. European journal of pharmacology. 2024-08-25. PMID:39182542. |
beyond insulin: the intriguing role of glp-1 in parkinson's disease. |
2024-08-25 |
2024-08-28 |
Not clear |
| Aanchal Verma, Ahsas Goya. Beyond Insulin: The Intriguing Role of GLP-1 in Parkinson's Disease. European journal of pharmacology. 2024-08-25. PMID:39182542. |
glp-1 (glucagon-like peptide 1) serves as both a peptide hormone and a growth factor, is released upon nutrient intake and contributes to insulin secretion stimulated by glucose levels. |
2024-08-25 |
2024-08-28 |
Not clear |
| Aanchal Verma, Ahsas Goya. Beyond Insulin: The Intriguing Role of GLP-1 in Parkinson's Disease. European journal of pharmacology. 2024-08-25. PMID:39182542. |
glp-1 receptor (glp-1r) agonists exhibit numerous implications like enhancement of glucose-dependent insulin release and biosynthesis, suppression of glucagon secretion and gastric emptying. |
2024-08-25 |
2024-08-28 |
Not clear |
| Erica Rosati, Gianfranco Di Giuseppe, Teresa Mezza, Pietro Manuel Ferrar. The influence of insulin and incretin-based therapies on renal tubular transport. Journal of nephrology. 2024-08-21. PMID:39167349. |
to our knowledge, this is the first review summarizing the effects induced on renal tubules by insulin, glucagon-like peptide-1 (glp-1) receptor agonists and serine protease dipeptidyl peptidase-4 (dpp4) inhibitors in both healthy and diabetic human subjects. |
2024-08-21 |
2024-08-24 |
human |
| Andrey Manov, Rakahn Haddadin, Sukhjinder Chauhan, Elizabeth Beng. Retrospective, Longitudinal, One-Group Study on the Implementation of Continuous Glucose Monitoring To Improve Quality of Care for Patients With Type I or II Diabetes Mellitus in an Internal Medicine Residency Continuity Community Clinic. Cureus. vol 16. issue 7. 2024-08-16. PMID:39149659. |
furthermore, 9.5% of the patients in this study eventually discontinued their daily insulin injections and continued treatment with oral diabetic medications with or without the use of injectable glp-1 receptors once a week. |
2024-08-16 |
2024-08-18 |
Not clear |
| Nicole Da Silva, G Harvey Anderson, Amira M Amr, Shirley Vien, Hrvoje Fabe. A Comparison of the Effects of Dairy Products with their Plant-based Alternatives on Metabolic Responses in Healthy Young Canadian Adults: a randomized cross-over study. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. 2024-08-15. PMID:39146559. |
in experiment 2, post-treatment insulin was higher after almond beverage compared to all treatments (p <0.01) and post-meal glp-1 was higher after milk than almond beverage (p =0.03). |
2024-08-15 |
2024-08-18 |
human |
| Nicole Da Silva, G Harvey Anderson, Amira M Amr, Shirley Vien, Hrvoje Fabe. A Comparison of the Effects of Dairy Products with their Plant-based Alternatives on Metabolic Responses in Healthy Young Canadian Adults: a randomized cross-over study. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. 2024-08-15. PMID:39146559. |
we conclude that the physiological functionality of plant-based alternatives as measured by blood glucose, insulin, c-peptide, and glp-1 did not replicate the metabolic functions of dairy products. |
2024-08-15 |
2024-08-18 |
human |
| James P Psaltis, Jessica A Marathe, Mau T Nguyen, Richard Le, Christina A Bursill, Chinmay S Marathe, Adam J Nelson, Peter J Psalti. Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future. Medicinal research reviews. 2024-08-14. PMID:39139038. |
they do so by activating pancreatic glp-1 receptors (glp-1r) to promote glucose-dependent insulin release and inhibit glucagon secretion. |
2024-08-14 |
2024-08-16 |
Not clear |